Approval equates to $1.8B or $72/share = $701.60/share value
Aren't they talking about a worst case low of 300 patients per year with that split among competing drugs? Even 2000 could be a very optimistic number.
Assuming AEGR is approved today and ISIS is denied tomorrow, I'll be happy with a pop to $22 rising to $25 by FDA approval at end of year.
Anything else is pie in the sky.